Clinical trials: Treatment Resistant Depressive Disorder
Major Depression
Antidepressant Effects of NR2B in Major Depression
Purpose : This study will determine whether MK-0657, a selective NR2B Antagonist, can quickly improve symptoms of depressed mood, psychomotor retardation, poor motivation and reduced enjoyment of things in patients with major…
- Trial name
- NCT00472576
- Testing
- MK-0657
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- National Institute of Mental Health (NIMH)
Bipolar Disorder, Bipolar Depression
Ketamine for Treatment-Resistant Bipolar Disorder
Growing evidence has supported rapid and robust antidepressant effects with subanesthetic doses of intravenous (IV) ketamine for treatment resistant depression (TRD).
- Conditions
- Bipolar Disorder, Bipolar Depression, Bipolar I Disorder, Bipolar II Disorder
- Trial name
- KET-BD (NCT05004896)
- Testing
- Ketamine Hydrochloride, Midazolam Hydrochloride
- Where
- 3 sites in Canada
- Volunteers
- 71 people
- Sponsor
- Joshua Rosenblat
Depression, Major Depressive Disorder
A Multiple Case Study of Schema Therapy for Difficult-to-treat Depression- DEPRE-ST*Case
This clinical multiple case study seeks to expand the knowledge of how schema therapy could function as an intervention for difficult-to-treat depression.
- Conditions
- Depression, Major Depressive Disorder, Chronic Depression, Treatment Resistant Depression
- Trial name
- NCT06655623
- Testing
- Schema therapy
- Where
- 2 sites in Denmark
- Volunteers
- 2 people
- Sponsor
- Region of Southern Denmark
Treatment Resistant Depression (TRD)
Ketamine Biomarker Validation
An EEG-based biomarker will be developed for the effects of ketamine infusion in patients with Depression. The effects of ketamine infusion on Depression symptoms and EEG signals will be analyzed.
- Trial name
- NCT07307768
- Testing
- Ketamine (0.25 mg/kg), Ketamine (0.5 mg/kg), Ketamine (0.75 mg/kg)
- Where
- United States
- Sponsor
- Soterix Medical
Resistant Major Depression
Pentoxifylline for Treatment of Resistant Major Depression
A growing body of evidence has highlighted the role of inflammation and phosphodiesterases (PDE)-related pathways in the pathogenesis of neuropsychiatric illnesses such as depression/mood disorders.
- Trial name
- NCT05324735
- Testing
- Pentoxifylline
- Where
- Iraq
- Volunteers
- 60 people
- Sponsor
- Hawler Medical University
Major Depressive Disorder, Treatment Resistant Depression
pBFS Guided rTMS Over Different Targets for Treatment-Resistant Depression
To explore the effectiveness and safety of rTMS intervention with different targets in the left prefrontal cortex defined using the pBFS method, in adult patients with moderate and severe depressive disorder.
- Conditions
- Major Depressive Disorder, Treatment Resistant Depression, MDD
- Trial name
- NCT06255561
- Testing
- active rTMS stimulating
- Volunteers
- 75 people
- Sponsor
- Changping Laboratory
Depressive Disorder, Treatment-Resistant
A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression
The purpose of this study is to assess the safety and tolerability of esketamine nasal spray in participants with treatment-resistant depression (TRD).
- Trial name
- SUSTAIN-3 (NCT02782104)
- Testing
- Esketamine Nasal Spray
- Where
- 173 sites in United States, Argentina and 24 more
- Volunteers
- 1,148 people
- Sponsor
- Janssen Research & Development, LLC
Eye Movement Desensitization and Reprocessing, Cognitive Behavioral Therapy
RCT Comparing EMDR and CBT for Treatment of Resistant Depression
Depression is one of the most common invalidating mental disorders, ranked by World Health Organization as the single largest contributor to global disability.
- Conditions
- Eye Movement Desensitization and Reprocessing, Cognitive Behavioral Therapy, Neurobiological Processing, Depression
- Trial name
- NCT03972033
- Testing
- EMDR, CBT
- Where
- Italy
- Volunteers
- 128 people
- Sponsor
- University of Turin, Italy
Cardiovascular Risk Factor, Diabetes Mellitus, Type 2
Evaluation of a Physical Activity Referral Scheme
The study will evaluate the effectiveness of a co-developed exercise referral scheme. Participants will be recruited to one of three groups 1. Co-developed exercise referral scheme, 2. Usual care exercise referral scheme, 3.
- Conditions
- Cardiovascular Risk Factor, Diabetes Mellitus, Type 2, Anxiety, Depression
- Trial name
- NCT03490747
- Testing
- Physical activity referral scheme, Usual care exercise referral scheme
- Where
- United Kingdom
- Volunteers
- 68 people
- Sponsor
- Paula Watson
Major Depressive Disorder
MRI Studies of Emotion in Depression
The purpose of this study is to research the effects of ketamine on brain function in patients with Major Depressive Disorder (MDD).
- Trial name
- NCT02429011
- Where
- United States
- Volunteers
- 135 people, healthy volunteers welcome
- Sponsor
- Icahn School of Medicine at Mount Sinai
Major Depressive Disorder
Pivotal Trial (D02) of Vagus Nerve Stimulation (VNS) for Treatment-Resistant Depression (TRD)
To confirm the safety and efficacy of the NCP System in treating patients in a nmajor depressive episode.
- Trial name
- NCT00533832
- Testing
- vagus nerve stimulation (VNS)
- Where
- United States
- Volunteers
- 266 people
- Sponsor
- Cyberonics, Inc.
Major Depressive Disorder, Treatment Resistant Depression
DBS for TRD With the Medtronic Percept PC
Of the estimated 30 million Americans who suffer from Major Depressive Disorder, approximately 10% are considered treatment resistant.
- Trial name
- NCT05773755
- Testing
- Medtronic Percept PC DBS system
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Helen Mayberg, MD
Treatment Resistant Depression, Generalized Anxiety Disorder
An Open Label Study of Clinical Utility and Patient Outcomes of the Genecept Assay
Genomind has developed and introduced a battery of genetic tests, the Genecept Assay, which clinicians can administer to patients using a simple saliva sample technique. The present study proposes to enroll 1.
- Trial name
- COM-1 (NCT01507155)
- Testing
- Genecept Assay
- Where
- United States
- Volunteers
- 685 people
- Sponsor
- Genomind, LLC
Depression - Major Depressive Disorder, Treatment-resistant Depression (TRD)
Biomarker-Guided Antidepressant Selection
Depression is one of the leading causes of disability worldwide. Common treatments like antidepressant medications and talk therapy work well for some people, but many others do not improve, even after trying multiple treatments.
- Conditions
- Depression - Major Depressive Disorder, Treatment-resistant Depression (TRD), rTMS, Ketamine
- Trial name
- BioSelect (NCT07680140)
- Testing
- TMS, Ketamine
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Weill Medical College of Cornell University
Depression, Major Depressive Disorder
eIMPACT-DM Pilot Trial: Depression Treatment to Reduce Diabetes Risk
This pilot randomized controlled trial seeks: (1) to determine the preliminary efficacy of our modernized collaborative care intervention for depression in improving the diabetes risk markers of hemoglobin A1c and insulin…
- Conditions
- Depression, Major Depressive Disorder, Dysthymic Disorder, Depressive Symptoms
- Trial name
- NCT04437485
- Testing
- Good Days Ahead (GDA), Problem Solving Treatment in Primary Care (PST-PC), Antidepressant Medications
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- Indiana University
Major Depressive Disorders
N-Acetyl Cysteine Supplementation in Therapy Refractory Major Depressive Disorders
The aim of this study is to evaluate the efficacy of N-acetylcysteine (NAC) add-on to antidepressant medication in treating patients who do not relieve during standard antidepressant treatment for 6 weeks at least.
- Trial name
- NCT02972398
- Testing
- N-acetylcysteine
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Tianjin Anding Hospital
Treatment Resistant Depression
Compressed Intermittent Theta Burst Stimulation
In this proposal the investigators will use an accelerated TMS protocol that concentrates the magnetic stimulation that would usually occur over 6 weeks into 10 treatment sessions per days, for 5 consecutive days in patient with…
- Trial name
- ciTBS (NCT04684706)
- Testing
- intermittent Theta Burst Stimulation
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- University of Pennsylvania
Major Depressive Disorder, Treatment Resistant Depression
MAO-B Occupancy in Depressed Patients
The study is looking at assessing monoamine oxidase B (MAO-B) occupancy in depressed patients before and after medication treatment using positron emission tomography (PET) scan.
- Trial name
- MOCP (NCT04841798)
- Testing
- [11C]SL25.1188 PET radiotracer
- Where
- Canada
- Volunteers
- 50 people
- Sponsor
- Centre for Addiction and Mental Health
Bipolar Depression, Treatment Resistant Bipolar Depression
FMRI of Patients Receiving IV Ketamine for Treatment Resistant Bipolar Depression
This is a prospective open-label observational study of patients with treatment resistant bipolar depression referred for intravenous ketamine, with an interventional component of fMRI.
- Trial name
- NCT06620042
- Testing
- Ketamine, Functional magnetic resonance imaging (fMRI)
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- Drew Cumming
Unipolar Depression
Ketamine Trial for the Treatment of Depression
This study is a Randomized Controlled Trial, investigating the safety and efficacy of administration of ketamine as a potential treatment for depression.
- Trial name
- NCT02401139
- Testing
- Ketamine
- Where
- 2 sites in Australia
- Volunteers
- 10 people
- Sponsor
- The University of New South Wales